摘要
目的了解医院ICU鲍氏不动杆菌的耐药性和临床分布特征,为临床预防该菌所致感染提供依据。方法对医院ICU 2007年1月-2009年12月分离的96株鲍氏不动杆菌按规程行药敏试验及结果分析。结果鲍氏不动杆菌在ICU的分离率逐年增加,其中82.3%的标本来源于下呼吸道;该菌多药耐药现象较严重,耐药率最低的抗菌药物是头孢哌酮/舒巴坦(2.1%),其次是美罗培南(14.6%)、亚胺培南(17.7%)。结论 ICU中鲍氏不动杆菌的多药耐药日趋严重,开展细菌耐药性监测,对指导临床合理使用抗菌药物、降低医院感染率和病死率有重要意义。
OBJECTIVE To provide the evidences for preventing the infections caused by bacteria, and to monitor the distribution and resistance of Acinetobacter baumannii in ICU. METHODS The distribution and drug susceptibility of 96 strains of A. baurnannii in nosocomial infections from 2007 to 2009 were retrospectively analyzed. RESULTS A. baumannii infections in hospital had increased in recent years. A. baumannii was mainly isolated from respiratory tract secretion samples （82.3 %）. The isolation rate of A. baumannii tended to rise. Its cross resistance to antibiotics was rather high. The resistant rate of A. baumannii to cefoperazone/sulbactam （2.1%） was the lowest, then to meropenem （14.6%） and imipenem （17.7% ）. CONCLUSION The antimicrobial resistance of A. baumannii is serious in ICU. It is urgent to carry out the surveillance to bacterial resistance for the rational use of antibiotics in order to decrease the morbidity and fatality rates.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2011年第1期156-157,共2页
Chinese Journal of Nosocomiology
关键词
重症监护病房
鲍氏不动杆菌
抗菌药物
耐药
Intensive care unit
Acinetobacter baurnannii
Antibiotics
Drug resistance
